A股異動 | 新易盛(300502.SZ)漲停 料上半年淨利大增疊加券商看好
格隆匯7月13日丨新易盛(300502.SZ)漲停,報76.14元,最新總市值252億。公司7月10日公告稱,預計今年上半年歸屬於上市公司股東的淨利潤1.8億至2億元,同比增123.15% - 147.95%。中信建投指,公司業績超預期,淨利潤維持高增長;海外數通市場400G升級,雲廠商追加基礎設施投資,光模塊需求旺盛,公司積極突破,收入有望再上一個台階。公司中報業績大超預期,高行業景氣度維持,我們上調公司盈利預測,預計2020-2021年的歸母淨利潤分別為3.97億元、5.53億元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.